Botulinum Toxin Type A

CHEMBL4297862 Phase 4 Aprobado Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A purified form of the toxin produced by Clostridium botulinum bacteria, used in tiny, precise doses to temporarily paralyze specific muscles. It is used therapeutically for conditions such as cervical dystonia, chronic migraine, excessive sweating, overactive bladder, and cosmetically to reduce facial wrinkles. Effects last for several months before repeat treatment is needed.

Áreas terapéuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A purified form of the toxin produced by Clostridium botulinum bacteria, used in tiny, precise doses to temporarily paralyze specific muscles. It is used therapeutically for conditions such as cervical dystonia, chronic migraine, excessive sweating, overactive bladder, and cosmetically to reduce facial wrinkles. Effects last for several months before repeat treatment is needed.

Yes, Botulinum Toxin Type A is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297862. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.